Clinical Trials Logo

Metastatic Breast Cancer clinical trials

View clinical trials related to Metastatic Breast Cancer.

Filter by:

NCT ID: NCT00555919 Completed - Clinical trials for Metastatic Breast Cancer

ZK 230211 in Postmenopausal Woman With Metastatic Breast Cancer

Start date: March 2008
Phase: Phase 2
Study type: Interventional

Randomized phase II study to investigate the efficacy, safety and tolerability of ZK 230211 (100 mg vs. 25 mg) as second-line endocrine therapy for postmenopausal women with hormone receptor-positive metastatic breast cancer.Once the cancer has spread beyond the lymph nodes to areas such as e.g. the skin, soft tissues, lung, and liver it is called metastatic breast cancer. Patients who have been diagnosed with metastatic breast cancer that has progressed since their previous cancer treatment and that cannot be removed completely by surgery are eligible to be treated within this trial.Treatment with a new drug called Progesterone Receptor Antagonist ZK 230211 (ZK PRA) targets the progesterone receptor which may be expressed on breast cancer tumour cells. Therefore only patients with this progesterone receptor on their tumour cells can be included in this study.Progesterone receptor antagonists (including onapristone) have already shown efficacy in postmenopausal women with advanced breast cancer (Klijn et al. 2000). This phase II study investigates the efficacy (proof of concept), safety and tolerability of ZK PRA at two dose levels (25 mg and 100 mg) before initiating pivotal phase III trials.

NCT ID: NCT00534417 Completed - Clinical trials for Metastatic Breast Cancer

Phase II Trial of Capecitabine With Fulvestrant for Postmenopausal Women With Hormone Receptor Positive Metastatic Breast Cancer

Start date: October 2007
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine if the combination of continuous daily capecitabine with fulvestrant on a loading dose schedule will delay disease progression in metastatic breast cancer (MBC) patients.

NCT ID: NCT00532623 Completed - Clinical trials for Metastatic Breast Cancer

Phase II Study of Gemcitabine/Vinorelbine vs Sequential Gemcitabine Followed by Vinorelbine in Metastatic Breast Cancer

Start date: May 2004
Phase: Phase 2
Study type: Interventional

To evaluate the overall response rate of gemcitabine and vinorelbine combination (GV) and gemcitabine followed by vinorelbine (G⇒V) when used as palliative therapy in patients with stage IV and recurrent breast cancer.

NCT ID: NCT00532272 Completed - Clinical trials for Metastatic Breast Cancer

Goserelin/Letrozole in Premenopausal Patients vs Letrozole Alone in Postmenopausal Patients With MBC

Start date: October 2005
Phase: Phase 2
Study type: Interventional

Primary objective is to evaluate the response rates and clinical benefits of letrozole + goserelin in premenopausal patients versus letrozole alone in postmenopausal patients with metastatic breast cancer as first line hormonal therapy

NCT ID: NCT00525096 Completed - Clinical trials for Metastatic Breast Cancer

Exemestane + Celecoxib vs Exemestane + Placebo in Metastatic Breast Cancer

Start date: July 2003
Phase: Phase 3
Study type: Interventional

To discover if the adding of a coxib increases the efficacy of the Aromasine.

NCT ID: NCT00524849 Completed - Clinical trials for Metastatic Breast Cancer

Zometa and Circulating Vascular Endothelial Growth Factor (VEGF) in Breast Cancer Patients With Bone Metastasis

Start date: November 2006
Phase: Phase 2/Phase 3
Study type: Interventional

The primary objective of this study is to evaluate the effects of Zometa (zoledronic acid, 1 mg per week versus 4 mg every four weeks) on the circulating vascular endothelial growth factor (VEGF) levels in breast cancer patients with bone metastases. Sixty patients will be randomized into two groups.

NCT ID: NCT00524810 Completed - Clinical trials for Metastatic Breast Cancer

Liposomal Doxorubicin and Docetaxel in Metastatic Breast Cancer

Start date: February 2004
Phase: Phase 2
Study type: Interventional

Evaluation of safety and efficacy of a treatment associating Pegylated Liposomal Doxorubicin + Docetaxel in patients with metastatic breast cancer

NCT ID: NCT00509769 Completed - Clinical trials for Metastatic Breast Cancer

A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) Administered Intravenously to Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer

Start date: July 2007
Phase: Phase 2
Study type: Interventional

This was a multi-institutional, open-label, single-arm, Phase II study of trastuzumab emtansine (T-DM1) administered by intravenous (IV) infusion to patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC).

NCT ID: NCT00508586 Completed - Clinical trials for Metastatic Breast Cancer

PTC299 and Hormonal Agent for Treatment of Metastatic Breast Cancer

Start date: November 2007
Phase: Phase 1
Study type: Interventional

Formation of new blood vessels (angiogenesis) is important for tumor growth in metastatic breast cancer. It is known that tumors make a protein called vascular endothelial growth factor (VEGF) and there are higher levels of VEGF in the tumors and blood of many women with metastatic breast cancer. VEGF stimulates the formation of blood vessels that supply the tumor with nutrients and oxygen. PTC299 is an oral drug that has been shown to decrease production of VEGF in animal models of human cancer. In these animal models, oral PTC299 administration decreases VEGF levels in the tumor and in the bloodstream, decreases blood vessel numbers in the tumor, and significantly slows or halts tumor growth. Safety studies in research animals indicate good tolerability at doses and drug levels that are higher than those planned for the clinical studies. Results from Phase 1a studies in healthy volunteers indicate that PTC299 achieves levels of PTC299 in the bloodstream that are known to be active in animal models of human cancer. This Phase 1b study is designed to test the hypothesis that PTC299 will be tolerable and will show evidence of VEGF reduction and antitumor activity when administered orally in combination with anastrozole (Arimidex®), letrozole (Femara®), or exemestane (Aromasin®) to women with metastatic breast cancer.

NCT ID: NCT00496665 Completed - Clinical trials for Metastatic Breast Cancer

ZD6474 (Zactima) and Metronomic Chemotherapy in Advanced Breast Cancer

Start date: July 2007
Phase: Phase 1
Study type: Interventional

The purpose of this research study is to determine the safety and tolerability of the combination of Zactima with metronomic chemotherapy. Zactima is an oral anti-angiogenesis drug, which means it fights cancer by cutting off a tumor's blood supply. Thus, the drug starves the tumor by preventing the delivery of nutrients and oxygen. Metronomic chemotherapy is low dose oral chemotherapy pills which are taken daily. Unlike traditional chemotherapy, metronomic chemotherapy is thought to fight cancer like Zactima, by cutting off the blood supply to tumors. Because the dose is very low, the side effects are generally mild and very different from those with higher dose chemotherapy given by vein.